Surface modification of medical or veterinary devices

Patent metadata

Field	Value
Publication number	US-2016193389-A1
Application number	US-201414898646-A
Country	US
Kind code	A1
Filing date	Jun 16, 2014
Priority date	Jun 19, 2013
Publication date	Jul 7, 2016
Grant date	—

Abstract

The invention concerns a medical or veterinary device comprising a covalently immobilized and cross-linked agarose coating, a method for the production of same and a cross-linked agarose coating.

First claim

1 . A medical or veterinary device comprising, on at least a part of its surface, a covalently immobilized and cross-linked agarose coating.

2 . The device according to claim 1 wherein said coating is provided on a surface selected from the group comprising: a biomaterial, silicone, polyurethane and titanium.

3 . The device according to claim 2 wherein said surface is a medical grade surface.

4 . The device according to claim 1 wherein said coating is provided on at least a part of the device that makes contact with a patient or animal.

5 . The device according to claim 1 wherein said agarose is modified by the introduction of one or more of acrylate, methacrylate, (meth)acrylamide, silane, thiol, azide, alkyne, vinylpyridine or vinylimidazole groups, or derivatives of these groups.

6 . The device according to claim 5 wherein said derivatives are selected from the group consisting of: acrylic anhydride, methacrylic chloride, N-hydroxyethyl (meth)acrylamide, 1-2-carboxyethyl-4-vinylpyridinium bromide, and 1-hydroxyethyl-3-vinylimidazolium bromide.

7 . The device according to claim 1 wherein said coating also comprises heparin.

8 . The device according to claim 7 wherein said heparin is modified by the introduction of one or more of methacrylate, acrylate, (meth)acrylamide, silane, thiol, azide, alkyne, vinylpyridine or vinylimidazole groups, or derivatives of these groups.

9 . The device according to claim 8 wherein said derivatives are selected from the group consisting of: acrylic anhydride, methacrylic chloride, N-hydroxyethyl (meth)acrylamide, 1-2-carboxyethyl-4-vinylpyridinium bromide, and 1-hydroxyethyl-3-vinylimidazolium bromide.

10 . The device according to claim 1 wherein said coating is 1-10 μm thick.

11 . The device according to claim 10 wherein the thickness of said coating is selected from the group comprising 1, 2, 3, 4 or 5 μm.

12 . The device according to claim 11 wherein said coating is about 2 μm thick.

13 . The device according to claim 7 wherein the amount of heparin in the coating is 1-15 μg/cm 2

14 . The device according to claim 13 wherein the amount of heparin in the coating is selected from the group consisting of: 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8 or 2.9 μg/cm 2 .

15 . The device according to claim 14 wherein the amount of heparin in the coating is about 2.6 μg/cm 2 .

16 . The device according to claim 1 wherein said device is a catheter.

17 . The device according to claim 16 wherein said catheter is selected from the group consisting of: a peritoneal dialysis catheter, a central venous catheter and a urinary catheter.

18 . A method for manufacturing a medical or veterinary device having, on at least a part of its surface, a covalently immobilized and cross-linked agarose coating, the method comprising:
i. oxidising a surface of said device; ii. exposing said oxidized surface to modified agarose; and iii. curing said surface.

19 . The method according to claim 18 wherein said agarose is modified by the addition of one or more of acrylate, methacrylate, (meth)acrylamide, silane, thiol, azide, alkyne, vinylpyridine or vinylimidazole groups, or derivatives of these groups.

20 . The method according to claim 19 wherein said derivatives are selected from the group consisting of: acrylic anhydride, methacrylic chloride, N-hydroxyethyl (meth)acrylamide, 1-2-carboxyethyl-4-vinylpyridinium bromide, and 1-hydroxyethyl-3-vinylimidazolium bromide.

21 . The method according to claim 18 wherein oxidising said surface involves exposing said surface to plasma treatment with gases selected from the group consisting of: argon, hydrogen, nitrogen and ammonia, followed by exposure to air.

22 . The method according to claim 18 wherein oxidising said surface involves corona discharge treatment or gamma irradiation treatment.

23 . The method according to claim 18 wherein said agarose is in aqueous solution.

24 . The method according to claim 23 wherein said solution comprises said agarose at 5 wt. %.

25 . The method according to claim 23 wherein said solution is dropped or sprayed onto the surface of the device.

26 . The method according to claim 25 wherein said solution is deposited using a spin-coating procedure.

27 . The method according to claim 23 wherein a surface of said device is immersed in said solution.

28 . The method according to claim 18 wherein said curing is undertaken in a degassed environment.

29 . The method according to claim 18 wherein said curing is undertaken using either Ultra violet (UV) light or heat.

30 . The method according to claim 29 wherein, in the instance where UV is used to cure said surface, the surface is exposed to UV for a time period between 15-120 min.

31 . The method according to claim 18 wherein said oxidised surface is also exposed to modified heparin.

32 . The method according to claim 31 wherein said heparin is modified by the introduction of one or more of methacrylate, acrylate, (meth)acrylamide, silane, thiol, azide, alkyne, vinylpyridine or vinylimidazole groups, or derivatives of these groups.

33 . The method according to claim 32 wherein said derivatives are selected from the group consisting of: acrylic anhydride, methacrylic chloride, N-hydroxyethyl (meth)acrylamide, 1-2-carboxyethyl-4-vinylpyridinium bromide, and 1-hydroxyethyl-3-vinylimidazolium bromide.

34 . The method according to claim 31 wherein said heparin is methacrylated.

35 . The method according to claim 31 wherein the amount of modified heparin in the coating is between 1-15 μg/cm 2 .

36 . The method according to any one of claim 34 wherein the amount of methacrylated heparin is ˜2.6m/cm 2 .

37 . The method according to any one of claims 18 - 36 wherein said coating is deposited to a thickness between 1-10 μm.

38 . The method according to claim 37 wherein said coating is deposited to a thickness of about 2 μm.

39 . The method according to claim 18 wherein said device is a catheter.

40 . The method according to claim 39 wherein said device is selected from the group consisting of: a peritoneal dialysis catheter, a central venous catheter and a urinary catheter.

41 . A catheter having, on at least a part of its surface, a covalently immobilized and cross-linked agarose coating.

42 . A catheter having, on at least a part of its surface, a covalently immobilized and cross-linked agarose and heparin coating.

43 . The catheter according to claim 42 wherein the amount of heparin is about 2.6 μg/cm 2 .

44 - 45 . (canceled)

Assignees

• Univ Singapore

Inventors

• Li Min
• Neoh Koon Gee
• Lau Titus Wai Leong
• Chiong Edmund
• Kang En Tang

Classifications

• A61L2420/06

  Coatings containing a mixture of two or more compounds · CPC title

• C08B37/0039

  Agar; Agarose, i.e. D-galactose, 3,6-anhydro-D-galactose, methylated, sulfated, e.g. from the red algae Gelidium and Gracilaria; Agaropectin; Derivatives thereof, e.g. Sepharose, i.e. crosslinked agarose · CPC title

• A61L29/043

  Polysaccharides · CPC title

• C09D105/12

  Agar-agar; Derivatives thereof · CPC title

• A61L29/085 Primary

  Macromolecular materials · CPC title